PRIMARY STUDY

Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies

Key Findings:  Two modalities, i.e. immunotherapy and cannabis, both that have immunomodulatory effects and may have possible interaction. This study was designed to examine the impact of cannabis-based therapies with that of immunotherapy. The researchers included a total of 140 patients (89 nivolumab alone, 51 nivolumab plus cannabis) with advanced melanoma, non-small cell lung cancer, and renal clear cell carcinoma. Results showed that the use of cannabis during immunotherapy treatment decreased response rate, without affecting progression-free survival or overall survival and without relation to cannabis composition.

Type of Study:  Meta-analysis

Study Sample Size:  140

Study Result:  Inconclusive

Study Location(s):  Israel

Year of Pub:  2019


Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC)

Phytocannabinoid Source:  Not Applicable